# Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

> **NCT03052478** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Vismodegib 150 mg

## Key facts

- **NCT ID:** NCT03052478
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-10
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-09-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052478, "Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03052478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*